HARBIN, China--(BUSINESS WIRE)--Renhuang Pharmaceuticals, Inc. (or "the Company", Stock symbol: RHGP.OB), a leading provider of natural health care products in the People's Republic of China (PRC), today announced that the Company has completed the R&D program for its Ribavirin Injection products and has submitted the application for approval to the SFDA (the State Food & Drug Administration, P.R.China).
